Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05199051
Other study ID # 2020/65
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 3, 2023
Est. completion date March 15, 2027

Study information

Verified date November 2023
Source Centre Antoine Lacassagne
Contact Céline CELLIER-COËLLE
Phone +33 492031778
Email DRCI-Promotion@nice.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a national, open-label, single-arm, multicenter phase II trial evaluating the safety and efficacy of adding gilteritinib, a new FLT3 inhibitor to the AGORA platform, consisting of the combination of an intermediate dose of cytarabine and a divided dose of GO in adult patients with R / R AML with an FLT3-ITD mutation.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date March 15, 2027
Est. primary completion date March 15, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients aged 18 years old or more - Confirmed diagnosis of R/R AML positive for CD33 antigen as determined locally by immunophenotyping according to routine practice, defined as: - AML refractory to 1 or 2 intensive chemotherapy courses or a treatment by hypomethylating agents (HMAs) - Or AML in first hematologic relapse or progression after front-line therapy, including intensive chemotherapy or hypomethylating agents (HMAs). - Previous treatments with FLT3 inhibitors (other than gilteritinib) are allowed - R/R AML secondary to a prior chemotherapy or radiotherapy for another cancer (tAML) could be included. - Presence of a FLT3-ITD mutation (allelic ratio =0.05 at last evaluation)* or a FLT3 TKD mutation - Patient with no contraindication to gemtuzumab ozogamicin (GO), cytarabine and gilteritinib - ECOG performance status =2 - AST and ALT = 2.5 x upper the limit of normal (ULN) and/or total and direct serum bilirubin = 1.5 x ULN unless considered due to leukemia - Estimated glomerular filtration rate (GFR) = 50 mL/min according to the formula usually used by the investigator - Written informed consent obtained prior to any screening procedures - Eligible for National Health Insurance in France Exclusion Criteria: - Acute promyelocytic leukemia or AML with BCR-ABL1 gene fusion - Secondary AML (sAML) defined by a history of prior myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPN) including chronic myelomonocytic leukemia (CMML) - Patient with contraindications to the administration of gemtuzumab ozogamicin (GO), cytarabine and gilteritinib. Refer to the SPCs of the molecules mentioned concerning the contraindications, special warnings, precautions for use, dose modifications in the event of toxicity, contraception and monitoring of patients and drugs prohibited or to be used with caution. - Proven central nervous system leukemic involvement - Prior allogeneic HSCT within the last 6 months and/or history of acute GVHD of grade >1 - Prior treatment with gemtuzumab ozogamicin within the last 3 months preceding the initiation of the treatment in the present clinical trial - Uncontrolled or active malignant disease within prior 12 months (excluding cutaneous basal cell carcinoma, "in-situ" carcinoma of the cervix or breast, or other local malignancy excised) - Uncontrolled or significant cardiovascular history or symptoms including: - Prior anthracycline exposure equivalent to more than 550 mg/m2 of daunorubicin - History of clinically relevant ventricular arrhythmias (e.g. ventricular tachycardia, ventricular fibrillation or torsade de pointes) - History of 2° (Mobitz II) or 3° heart block (subjects with pacemakers are allowed if they have no history of clinically relevant arrhythmias with the pacemaker) - History of uncontrolled angina pectoris or MI within 6 months - History of NYHA Class 3 or 4 heart failure - Left ventricular ejection fraction = 50% or less than the institutional lower limit of normal - History of complete left bundle branch block - Unstable angina, New York Heart Association (NYHA) class 3 or 4 congestive heart failure - QTcF > or equal to 450 msec, long QT syndrome (including family history) - Bradycardia < 50 bpm (unless subject has a pacemaker) - Systolic BP = 180 mmHg or diastolic BP = 110 mmHg - Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate treatment) - Active known HBV or HCV hepatitis or positive HIV serology - Concurrent therapy with any other investigational agent or cytotoxic drug, within 28 days before starting treatment. Only hydroxyurea ± dexamethasone is permitted for the control of blood counts - Current use or anticipated requirement for drugs that are known strong inducers of CYP3 A4/5 - Current use or anticipated requirement for drugs that are known as strong inhibitors or inducers of P glycoprotein (P-gp), as mentioned in the appendix 14 of the protocol, with the exception of drugs that are considered absolutely essential for the care of the subject - Current use or anticipated treatment with concomitant drugs that target 5HT1R or 5HT2BR receptors or sigma non-specific receptor, as mentioned in the appendix 15 of the protocol, with exception of drugs that are considered absolutely essential for the care of the subject - Known malabsorption syndrome or other condition that may significantly impair absorption of oral study medications - Any of concurrent severe and/or uncontrolled medical condition, which could compromise participation in the study. - Patient currently receiving one or more inadvisable or prohibited treatments described in section 6.4.2 of the protocol. - Females who are pregnant or breastfeeding. - Women of childbearing potential or partners of women of childbearing potential should use a highly effective method of contraception during treatment and change the duration of contraception after the last dose of the medicines of the study (GO, cytarabine and gilteritinib). - For women of childbearing potential (WOCBP): agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception with a failure rate of < 1% per year during the treatment period and after the final dose of study treatment for at least: - 7 months for GO, - 6 months for cytarabine, - 6 months for gilteritinib. Women must refrain from donating eggs during this same period. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization is permanently infertile due to surgery (i.e. removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. If required per local guidelines or regulations, locally recognized acceptable methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form. Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to first dose. - For male patients: acceptance that most of the study treatments require specific reliable and effective contraception measures, as well as measures related to sperm donation Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm, as defined below With a female partner of childbearing potential who is not pregnant, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and after the final dose of study treatment for at least: - 4 months for GO, - 6 months for cytarabine, - 4 months for gilteritinib. Men must refrain from donating sperm during this same period With pregnant female partners, men must remain abstinent or use a condom to avoid exposing the embryo during the treatment period and for at least: - 4 months for GO, - 6 months for cytarabine, - 4 months for gilteritinib. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. If required per local guidelines or regulations, locally recognized acceptable methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form. - Adults subject to a legal protection order or unable to give their consent - Persons deprived of their freedom by judicial or administrative decision, persons hospitalized without their consent by virtue of articles L. 3212-1 and L. 3213-1 and who are not subject to the provisions of article L. 1121-8.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Gemtuzumab ozogamicine - Cytarabine - Gilteritinib
See Arms description paragraph

Locations

Country Name City State
France CHU d'Amiens Amiens
France CHU d'Angers Angers
France CH Victor Dupouy Argenteuil
France Hôpital Avicenne Bobigny
France CHU Bordeaux Bordeaux
France CHU de Caen Caen
France CHMS de Chambery Chambery
France HIA Percy Clamart
France CHU Henri Mondor Créteil
France CHU Dijon Dijon
France CHU Limoges Limoges
France Centre Léon Bérard Lyon
France Hôpital Lyon sud Lyon
France Hôpital la Timone Conception Marseille
France CH de Meaux Meaux
France CHRU Nancy Nancy
France CHU Nantes Nantes
France CHR Orléans Orléans
France Hôpital de la Pitié Salpétrière Paris
France Hôpital Necker Paris
France Hôpital Saint Louis Paris
France CHU Poitiers Poitiers
France CH René Dubos Pontoise
France CHU Robert Debré Reims
France CHU Pontchaillou Rennes
France Centre Henri Becquerel Rouen
France CHRU Bretonneau Tours
France Centre Hospitalier de Versailles Versailles
France IGR Villejuif

Sponsors (2)

Lead Sponsor Collaborator
Centre Antoine Lacassagne Acute Leukemia French Association

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Stage 1 - Safety of the addition of gilteritinib to the AGORA treatment platform The primary objective of the first stage is to evaluate the safety of combining gilteritinib with the Gemtuzumab Ozogamicin (GO) -cytarabine AGORA platform in patients with FLT3-ITD mutated Relapse/Refractory (R/R) Acute Myeloïd Leukemia (AML), through occurrence of dose-limiting toxicity (DLT). 18 months
Primary Stage 2 - Event-free survival (EFS) The primary objective of the second extension stage is to evaluate the efficacy of combining gilteritinib with the Gemtuzumab Ozogamicin (GO)-cytarabine AGORA platform in patients with FLT3-ITD mutated Relapse/Refractory (R/R) Acute Myeloïd Leukemia (AML) through event-free survival (EFS). 60 months
Secondary Response rates to the study treatment Response rate, including Complete Response (CR), Incomplete Hematologis Recovery (CRi) and partial hematologic recovery (CRh)*; the overall response rate (ORR) being defined as CR/CRi/CRh rates
*: CRi, CR with incomplete hematologic recovery, meaning CR with platelet count <100,000/µL or absolute neutrophil count <1000/µL; CRh, CR with partial hematologic recovery, meaning CR not fulfilling CR or CRi criteria but with platelet count >50,000/µL AND absolute neutrophil count >500/µL.
60 months
Secondary Early mortality rates, at day-30 Mortality rates between day 1 and day 30 30 months
Secondary Incidence of subsequent allogeneic Hematopoietic Stem Cell Transplantation (HSCT) overall. Incidence of subsequent allogeneic HSCT of all patients of the study. 60 months
Secondary Incidence of subsequent allogeneic Hematopoietic Stem Cell Transplantation in responding patients specifically. Incidence of subsequent allogeneic HSCT in responding patients specifically. 60 months
Secondary Evaluation of Duration of response (DOR) of treatment Duration of response (DOR). 60 months
Secondary Evaluation of relapse-free survival (RFS) Duration of relapse-free survival (RFS) of patient. 60 months
Secondary Evaluation of overall survival (OS) Duration of overall survival (OS) defined as the time between the date of the inclusion and the date of death or the date of last news for those still alive at the end of the follow-up. 60 months
Secondary Subgroup analyses defined by patient Subgroups defined by a patient related factor: age (<65 vs =65y) 60 months
Secondary Subgroup analyses defined by disease Subgroups defined by disease related factors: cytogenetics, mutation profiles (including NPM1 and FLT3-ITD), ELN-risk classification 2017. 60 months
Secondary Subgroup analyses defined by allograft Subgroups defined by treatment related factor by the performance of a subsequent allogeneic HSCT. 60 months
Secondary Evaluation of the Safety : incidence of SAE (SAEs) Safety through Serious Adverse event (SAEs) 60 months
Secondary Evaluation of the Safety : incidence of Adverses Events (AEs) Safety through Adverse event (AEs), Serious Adverse event (SAEs), Treatment Emergent Adverse Event (TEAEs) and incidence of sinusoidal obstruction syndrome (SOS)) 60 months
Secondary Evaluation of the Safety : incidence of Treatment Emergent Adverse Event (TEAEs) Safety through Treatment Emergent Adverse Event (TEAEs) 60 months
Secondary Evaluation of the Safety : incidence of sinusoidal obstruction syndrome (SOS) Safety through incidence of sinusoidal obstruction syndrome (SOS) 60 months
See also
  Status Clinical Trial Phase
Completed NCT03118466 - Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT06313437 - Revumenib in Combination With 7+3 + Midostaurin in AML Phase 1
Withdrawn NCT03444649 - Epacadostat, Idarubicin and Cytarabine (EIC) in AML Phase 1
Withdrawn NCT02905994 - Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia Phase 1
Recruiting NCT02261779 - Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Phase 1/Phase 2
Completed NCT00246649 - Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia N/A
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Terminated NCT04079738 - Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib Phase 1/Phase 2
Completed NCT03466320 - DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Phase 1/Phase 2
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Terminated NCT01570465 - Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
Completed NCT04443751 - A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 1
Terminated NCT03761069 - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Phase 1
Completed NCT02631993 - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia N/A
Completed NCT02575963 - Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients Phase 1/Phase 2
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Completed NCT00780598 - Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Phase 2
Completed NCT00761449 - Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 Phase 2
Completed NCT00542971 - Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Phase 1/Phase 2
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A